Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX3 CL1/CX3 CR1 Pathway in Experimental Mouse Models of Systemic Sclerosis.
Vu H LuongAkira UtsunomiyaTakenao ChinoLe H DoanhTakashi MatsushitaTakashi ObaraYoshikazu KuboiNaoto IshiiAkihito MachinagaHideaki OgasawaraWataru IkedaTetsu KawanoToshio ImaiNoritaka OyamaMinoru HasegawaPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
Anti-CX3 CL1 mAb therapy may be a novel approach for treating early skin fibrosis in inflammation-driven fibrotic skin disorders such as SSc.